The endocannabinoid system is a group of receptors and transmitters in the brain and nervous system that regulate many physiological and psychological processes in the human body. In medical trials of new drugs, human safety is the primary concern and each new product must show at what dosage its use becomes fatal. The advantage of cannabinoid medicines is that they have no known fatal dose. Producing effective therapies also requires the delivery of medicines in standardized and metered concentrations. CannScience and its partners are committed to ensuring the highest global standards for our cannabinoid medicines.
For further information about R&D Facilities, please click here.